AURINIA PHARMACEUTICALS INC (AUPH) Stock Fundamental Analysis
USA - NASDAQ:AUPH - CA05156V1022 - Common Stock
13.14 USD
+0.29 (+2.26%)
13.13 USD
-0.01 (-0.08%)
We assign a fundamental rating of 6 out of 10 to AUPH. AUPH was compared to 538 industry peers in the Biotechnology industry. While AUPH has a great health rating, its profitability is only average at the moment. AUPH is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, AUPH could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
AUPH had positive earnings in the past year.
AUPH had a positive operating cash flow in the past year.
AUPH had negative earnings in 4 of the past 5 years.
In the past 5 years AUPH reported 4 times negative operating cash flow.
1.2 Ratios
AUPH has a better Return On Assets (12.07%) than 94.80% of its industry peers.
The Return On Equity of AUPH (18.08%) is better than 95.35% of its industry peers.
Looking at the Return On Invested Capital, with a value of 12.56%, AUPH belongs to the top of the industry, outperforming 94.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.07% | ||
| ROE | 18.08% | ||
| ROIC | 12.56% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of AUPH (23.31%) is better than 95.54% of its industry peers.
Looking at the Operating Margin, with a value of 26.53%, AUPH belongs to the top of the industry, outperforming 95.91% of the companies in the same industry.
AUPH has a better Gross Margin (89.51%) than 91.45% of its industry peers.
In the last couple of years the Gross Margin of AUPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.53% | ||
| PM (TTM) | 23.31% | ||
| GM | 89.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AUPH is still creating some value.
The number of shares outstanding for AUPH has been reduced compared to 1 year ago.
Compared to 5 years ago, AUPH has more shares outstanding
Compared to 1 year ago, AUPH has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.34 indicates that AUPH is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.34, AUPH is in the better half of the industry, outperforming 76.95% of the companies in the same industry.
The Debt to FCF ratio of AUPH is 0.82, which is an excellent value as it means it would take AUPH, only 0.82 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.82, AUPH belongs to the top of the industry, outperforming 95.17% of the companies in the same industry.
AUPH has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
AUPH has a Debt to Equity ratio of 0.18. This is in the lower half of the industry: AUPH underperforms 67.66% of its industry peers.
Even though the debt/equity ratio score it not favorable for AUPH, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.82 | ||
| Altman-Z | 5.34 |
ROIC/WACC1.38
WACC9.09%
2.3 Liquidity
AUPH has a Current Ratio of 5.23. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
AUPH has a Current ratio (5.23) which is comparable to the rest of the industry.
A Quick Ratio of 4.63 indicates that AUPH has no problem at all paying its short term obligations.
With a Quick ratio value of 4.63, AUPH perfoms like the industry average, outperforming 52.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.23 | ||
| Quick Ratio | 4.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 243.33% over the past year.
The Revenue has grown by 25.59% in the past year. This is a very strong growth!
The Revenue has been growing by 279.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)243.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1500%
Revenue 1Y (TTM)25.59%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%22.41%
3.2 Future
Based on estimates for the next years, AUPH will show a very strong growth in Earnings Per Share. The EPS will grow by 68.12% on average per year.
The Revenue is expected to grow by 12.58% on average over the next years. This is quite good.
EPS Next Y642.33%
EPS Next 2Y197.32%
EPS Next 3Y119.25%
EPS Next 5Y68.12%
Revenue Next Year14.36%
Revenue Next 2Y14.39%
Revenue Next 3Y14.64%
Revenue Next 5Y12.58%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
AUPH is valuated quite expensively with a Price/Earnings ratio of 30.56.
Compared to the rest of the industry, the Price/Earnings ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 92.94% of the companies listed in the same industry.
AUPH's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.32.
With a Price/Forward Earnings ratio of 16.52, AUPH is valued correctly.
94.24% of the companies in the same industry are more expensive than AUPH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.89, AUPH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.56 | ||
| Fwd PE | 16.52 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 94.80% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, AUPH is valued cheaply inside the industry as 94.98% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.72 | ||
| EV/EBITDA | 13.45 |
4.3 Compensation for Growth
AUPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AUPH's earnings are expected to grow with 119.25% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y197.32%
EPS Next 3Y119.25%
5. Dividend
5.1 Amount
AUPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.14
+0.29 (+2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners47.03%
Inst Owner Change-4.66%
Ins Owners2.23%
Ins Owner Change-0.39%
Market Cap1.73B
Analysts81.67
Price Target11.95 (-9.06%)
Short Float %7.33%
Short Ratio4.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.91%
Min EPS beat(2)6.95%
Max EPS beat(2)56.86%
EPS beat(4)4
Avg EPS beat(4)194.67%
Min EPS beat(4)6.95%
Max EPS beat(4)553.6%
EPS beat(8)7
Avg EPS beat(8)113.5%
EPS beat(12)11
Avg EPS beat(12)90.5%
EPS beat(16)13
Avg EPS beat(16)66.94%
Revenue beat(2)1
Avg Revenue beat(2)3.64%
Min Revenue beat(2)-0.48%
Max Revenue beat(2)7.75%
Revenue beat(4)2
Avg Revenue beat(4)5.09%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)15.16%
Revenue beat(8)5
Avg Revenue beat(8)8.08%
Revenue beat(12)9
Avg Revenue beat(12)11.98%
Revenue beat(16)13
Avg Revenue beat(16)10.05%
PT rev (1m)0.18%
PT rev (3m)15.51%
EPS NQ rev (1m)-2.04%
EPS NQ rev (3m)8.11%
EPS NY rev (1m)0%
EPS NY rev (3m)11.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.56 | ||
| Fwd PE | 16.52 | ||
| P/S | 6.65 | ||
| P/FCF | 18.72 | ||
| P/OCF | 18.66 | ||
| P/B | 5.16 | ||
| P/tB | 5.22 | ||
| EV/EBITDA | 13.45 |
EPS(TTM)0.43
EY3.27%
EPS(NY)0.8
Fwd EY6.05%
FCF(TTM)0.7
FCFY5.34%
OCF(TTM)0.7
OCFY5.36%
SpS1.98
BVpS2.55
TBVpS2.52
PEG (NY)0.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.07% | ||
| ROE | 18.08% | ||
| ROCE | 16.26% | ||
| ROIC | 12.56% | ||
| ROICexc | 48.78% | ||
| ROICexgc | 50.66% | ||
| OM | 26.53% | ||
| PM (TTM) | 23.31% | ||
| GM | 89.51% | ||
| FCFM | 35.52% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score8
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.82 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.54% | ||
| Cap/Sales | 0.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 104.75% | ||
| Profit Quality | 152.36% | ||
| Current Ratio | 5.23 | ||
| Quick Ratio | 4.63 | ||
| Altman-Z | 5.34 |
F-Score8
WACC9.09%
ROIC/WACC1.38
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)243.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1500%
EPS Next Y642.33%
EPS Next 2Y197.32%
EPS Next 3Y119.25%
EPS Next 5Y68.12%
Revenue 1Y (TTM)25.59%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%22.41%
Revenue Next Year14.36%
Revenue Next 2Y14.39%
Revenue Next 3Y14.64%
Revenue Next 5Y12.58%
EBIT growth 1Y230.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6475.33%
EBIT Next 3Y383.48%
EBIT Next 5YN/A
FCF growth 1Y329.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y335.18%
OCF growth 3YN/A
OCF growth 5YN/A